基于生物信息学分析的潜在诊断标志物和阻塞性睡眠呼吸暂停与并发性抑郁症的治疗标
Yinfei Lu1, Zao Tang2, Xiangyu Zhou3
1Department of Geriatrics, WuHan Red Cross Hospital, Wuhan, Hubei Province, China.
Frontiers in genetics
|December 5, 2025
概括
研究人员确定CD74和RPL26L1是阻塞性睡眠呼吸暂停 (OSA) 和主要抑郁症 (MDD) 伴随性疾病的关键生物标志物. 这些发现表明,在两种条件下改善患者结果的新型治疗点.
科学领域:
- 基因组学和生物信息学
- 免疫学 免疫学 免疫学
- 睡眠医学 睡眠医学
背景情况:
- 阻塞性睡眠呼吸暂停 (OSA) 和严重抑郁症 (MDD) 显著影响生活质量,并带来高的社会经济成本.
- 有证据表明,OSA和MDD之间存在双向关系,恶化了临床结果.
- 了解这种并发症的分子基础对于开发有效的治疗方法至关重要.
研究的目的:
- 为了确定OSA-MDD并发症的诊断生物标志物.
- 探索OSA和MDD同时发生的潜在治疗点.
- 调查OSA-MDD中涉及的共享分子通路.
主要方法:
- 来自基因表达大巴 (GEO) 的OSA/MDD数据集的差异基因表达分析.
- 权重基因共同表达网络分析 (WGCNA) 和蛋白质-蛋白质相互作用 (PPI) 网络分析以确定关键基因.
- LASSO回归用于诊断标志物选择,其次是免疫关联和体外验证.
主要成果:
- 在合并性OSA-MDD中鉴定了77个差异表达基因 (DEGs).
- 通过WGCNA-PPI综合分析,发现了8个关键的枢纽基因.
- CD74和RPL26L1被提名为诊断标记物,显示与免疫细胞透和在体外缺氧下上调的相关性.
结论:
- CD74和RPL26L1作为OSA-MDD的机械验证的诊断生物标志物.
- 这些基因代表着有希望的治疗点,用于管理并发性OSA和MDD.
- 共享的分子通路为患有这两种疾病的患者提供了新的干预途径.
更多相关视频
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
497
07:58Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
Published on: February 24, 2023
798
相关概念视频
Sleep Apnea
452
Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
The condition is more prevalent among...
452
Depression: Overview
750
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
750
Depressive Disorders: Etiology
415
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
415
Antidepressant Drugs: MAOIs and Other Agents
774
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
774
